Thus, by shifting the gut microbiota toward a healthier profile, GLP-1 agonists help disrupt the vicious cycle of obesity-induced gut dysbiosis and inflammation. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.